Overview

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
0
Participant gender:
All
Summary
To determine the utility of tissue plasminogen activator (tPA) in the clearance of chronic subdural hematomas (CSDH). Intra-catheter tPA will be administered during surgical procedure and allowed to break down blood clot to assist with removal/drainage during twist drill craniostomy procedure.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hamilton Health Sciences Corporation
Treatments:
Plasminogen
Tissue Plasminogen Activator
Criteria
Inclusion Criteria:

1. Adult patients (18 yrs or older)

2. Admitted to neurosurgery wing at the hospital

3. Symptomatic patients requiring surgical drainage by twist drill craniostomy

Exclusion Criteria:

1. Patients at increased risk of bleeding such as patients taking anticoagulation
medication that required reversal at time of interventionŲŒ or those with coagulopathic
disorder.

2. Patients on antiplatelets or anticoagulation medications (DOACs or warfarin) with
appropriate holding period prior to drainage, those who are eventually minimized to a
regular bleeding risk compared to the normal population, will be included in the
study.

3. Patients with subdural empyema.

4. Redo twist drill craniostomy for residual cSDH within the same admission.

5. Drain accidentally removed during nursing care or patient transport before 24 hr
interval scan.

6. Patients who are not expected to live more than three months.